within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BX13_RosuvastatinPerindoprilAndIndapa;

model RosuvastatinPerindoprilAndIndapa
  extends Pharmacolibrary.Drugs.ATC.C.C10BX13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>RosuvastatinPerindoprilAndIndapamide</td></tr><tr><td>ATC code:</td><td>C10BX13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination medication containing rosuvastatin (a statin used to lower cholesterol), perindopril (an ACE inhibitor used for hypertension), and indapamide (a thiazide-like diuretic for hypertension and heart failure). Used for cardiovascular risk reduction and hypertension control. This combination is approved and is marketed in some countries.</p><h4>Pharmacokinetics</h4><p>No published studies currently available reporting pharmacokinetic parameters for the fixed-dose combination (FDC) of rosuvastatin/perindopril/indapamide as triple therapy. The following parameters are estimated based on published PK data of the individual components in healthy adult subjects.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end RosuvastatinPerindoprilAndIndapa;
